5.27-6.2 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

Jazz Pharmaceuticals plc revealed that the U.S. Food and Drug Administration (FDA) has accepted and given Priority Review status to the Biologics License Application (BLA) for zanidatamab.

Full-Life Technologies Receives FDA IND Clearance for 225Ac-FL-020 to Treat Metastatic Castration-Resistant Prostate Cancer.

VBI Vaccines Releases New Tumor Response Results from Ongoing Phase 2b Study of VBI-1901 in Patients with Recurrent Glioblastoma.

CDR-Life Inc. has started enrolling participants for the Phase 1 clinical trial of CDR404, their leading candidate being developed as a targeted immunotherapy for the treatment of solid tumors.

LIB Therapeutics Shares Positive Phase 3 Lerodalcibep Results at 92nd European Atherosclerosis Society Congress.

Atara Biotherapeutics Presents Early Research on ATA3219, a CAR T Therapy Targeting CD19 for B-Cell Autoimmune Diseases, at ISCT 2024.

The partnership involves the commercialization and licensing of BAT2506, a biosimilar of Simponi® (golimumab).

Outlook Therapeutics® Gains European Commission Approval for Marketing LYTENAVA™ (bevacizumab gamma) to Treat Wet AMD.

May 31st latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The U.S. Food and Drug Administration has granted approval to Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) for the treatment of specific rare conditions.

In the TROPION-Lung01 Phase III trial, datopotamab deruxtecan significantly improved overall survival compared to chemotherapy in patients with advanced nonsquamous non-small cell lung cancer.